Belimumab (BENLYSTA®) Pregnancy Registry
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01532310 |
Recruitment Status :
Completed
First Posted : February 14, 2012
Last Update Posted : January 23, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Systemic Lupus Erythematosus | Drug: belimumab |
Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 77 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 9 Years |
Official Title: | WEUKBRE6076: Belimumab (BENLYSTA) Pregnancy Registry Protocol |
Actual Study Start Date : | July 16, 2012 |
Actual Primary Completion Date : | November 11, 2022 |
Actual Study Completion Date : | November 11, 2022 |

Group/Cohort | Intervention/treatment |
---|---|
Pregnant women taking belimumab
Any women with belimumab exposure within the 4 months prior to and/or during pregnancy
|
Drug: belimumab
Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus |
Infants
Infants through the first year of life whose mothers were exposed to belimumab during pregnancy
|
Drug: belimumab
Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus |
- Birth defects [ Time Frame: Up to one year after birth ]The registry will define and code birth defects with criteria specified by Centers for Disease Control and Prevention (CDC)'s Metropolitan Atlanta Congenital Defects Program (MACDP)
- Other pregnancy outcomes [ Time Frame: At birth ]Other pregnancy outcomes including spontaneous miscarriage, live birth (including pre-term birth and small for gestational age), stillbirth, and elective termination
- Infant outcomes [ Time Frame: Up to 1 year after birth ]Serious and/or clinically significant infections

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Pregnant women containing sufficient evidence to confirm that exposure to commercially supplied belimumab occurred within the 4 months prior to and/or during pregnancy
- Pregnant women with sufficient information to classify the pregnancy as prospective or retrospective (ie,whether the outcome of pregnancy was known at the time of first contact with the registry)
- Pregnant women with full contact information to allow for follow-up (name, address, telephone number/email address) and contact information for applicable HCPs if initial reporter is the pregnant woman
- Consent provided by the pregnant woman for her participation and assent for participation of her infant.
Exclusion Criteria:
- Reported cases that do not meet the minimum inclusion criteria for registry enrollment will be ineligible for inclusion in the registry

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01532310
United States, North Carolina | |
GSK Investigational Site | |
Wilmington, North Carolina, United States, 28401-3331 | |
GSK Investigational Site | |
Wilmington, North Carolina, United States, 28401 | |
Argentina | |
GSK Investigational Site | |
La Plata, Buenos Aires, Argentina, B1902COS | |
Austria | |
GSK Investigational Site | |
Innsbruck, Austria, 6020 | |
Belgium | |
GSK Investigational Site | |
Liège, Belgium, 4000 | |
Canada, Quebec | |
GSK Investigational Site | |
St Laurent, Quebec, Canada, H4T 1V6 | |
France | |
GSK Investigational Site | |
Paris Cedex 13, France, 75651 | |
Germany | |
GSK Investigational Site | |
Duesseldorf, Nordrhein-Westfalen, Germany, 40225 | |
Israel | |
GSK Investigational Site | |
Ramat-Gan, Israel, 52621 | |
Italy | |
GSK Investigational Site | |
Pisa, Toscana, Italy, 56126 | |
Portugal | |
GSK Investigational Site | |
Almada, Portugal, 2805-267 | |
Spain | |
GSK Investigational Site | |
Bilbao, Spain, 48013 | |
Sweden | |
GSK Investigational Site | |
Stockholm, Sweden, SE-17176 | |
Switzerland | |
GSK Investigational Site | |
Bern, Switzerland, 3010 | |
GSK Investigational Site | |
St. Gallen, Switzerland, 9007 | |
GSK Investigational Site | |
Zürich, Switzerland, 8006 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Publications:
Responsible Party: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT01532310 |
Other Study ID Numbers: |
114256 WEUKBRE6076 ( Other Identifier: GSK ) |
First Posted: | February 14, 2012 Key Record Dates |
Last Update Posted: | January 23, 2023 |
Last Verified: | January 2023 |
systemic lupus erythematosus belimumab pregnancy |
Lupus Erythematosus, Systemic Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |
Belimumab Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |